You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Feasibility of a mobile application for sleep and circadian rhythms in pediatric patients with acute lymphoblastic leukemia and their caregivers

    SBC: ARCASCOPE INC.            Topic: NHLBI

    ABSTRACT Long-term survival rates for children diagnosed with acute lymphoblastic leukemia (ALL) currently exceed 90%. However, prolonged ALL chemotherapy, which lasts two to three years on average, is associated with significant fatigue and sleep disturbances in both children and their caregivers. In fact, patients and caregivers often identify excess fatigue and sleep disturbances as the most di ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Using in-vivo Real-time Biosensor to Evaluate Prodrugs Designed to Prolong Therapeutic Effects for Smoking Cessation.

    SBC: SPACERX LLC            Topic: NIDA

    ABSTRACT Developing drugs that target the central nervous system (CNS) is hampered by an inability to perform direct in vivo preclinical measurements. Here, we propose to identify an optimal smoking cessation drug candidate by monitoring how our newly synthesized prodrugs alter real-time brain dopamine responses to nicotine. Varenicline (CHANTIX®) is the leading FDA-approved oral medication for s ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Pigment Sensing Pulse Oximeter Technology for Mitigating Racial Bias in Oxygen Saturation Measurements

    SBC: PENDERIA TECHNOLOGIES, INC.            Topic: 100

    Abstract Wearable pulse oximetry sensors are among the most ubiquitous medical technologies used in healthcare. Clinicians rely on pulse oximeters to monitor patient health during disease states and medical procedures. However, numerous studies have shown this technology to be racially biased; hypoxemia is three times more likely to go undetected in patients with dark skin compared to those with l ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Drug Delivery Platform as Medical Countermeasure for treatment of Gastrointestinal Radiation Damage

    SBC: THE TINY CARGO COMPANY            Topic: 102

    Project Summary/Abstract The Tiny Cargo Company offers a unique, orally administered medical countermeasure for treatment and prevention of the gastrointestinal (GI) side effects of cancer radiation therapy (RT). Our therapeutic is comprised of milk-derived extracellular vesicles (mEVs) loaded with a safe and highly effective radioprotective drug – a formulation that we call Milactatm. RT compli ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Making Mindfulness-Based Cognitive Therapy accessible for underserved pregnant people: Developing Center M for commercialization

    SBC: CENTER MOM, INC.            Topic: 104

    PROJECT SUMMARY/ABSTRACT A highly effective intervention to prevent perinatal depression, mindfulness-based cognitive therapy for perinatal depression (MBCT), exists; however, critical implementation gaps prevent its wide use. And though universally recommended, not all prenatal care clinics effectively screen for perinatal depression (PD). Overcoming current implementation gaps is imperative to a ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Antisense Oligonucleotides to Regulate Gamma' Fibrinogen Levels

    SBC: Gamma Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT g' (pronounced "gamma prime") fibrinogen (GPF) is an alternative splice isoform of the blood coagulation factor fibrinogen. This fibrinogen variant contains a high affinity binding site for the coagulation factor thrombin that localizes thrombin on the growing blood clot. Thrombin binds to GPF via thrombin's heparin binding site. This allows thrombin to continue forming th ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. A novel therapeutic for the treatment of biofilms in periprosthetic joint infections

    SBC: QENTOROS LLC            Topic: NIAID

    PROJECT SUMMARY Total joint arthroplasty (TJA) procedures are estimated to rise by over 300% by the year 2030. Periprosthetic joint infection (PJI) is the most significant complication following TJA with healthcare costs exceeding $1.6 billion annually. Treatment of PJI generally requires surgical intervention combined with a prolonged course of antibiotics costing $50,000 per patient. Despite thi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Light-directed therapy of squamous cell head and neck cancer with a novel dual-acting chemotherapeutic.

    SBC: LIGHT SWITCH BIO, LLC            Topic: 102

    PROJECT SUMMARY. In this Phase I STTR project, Light Switch Bio will collaborate with Virginia Commonwealth University and the University of Pennsylvania for the early-stage development of IR-Platin, a first-in-class photoactivated chemotherapy for treatment of head and neck squamous cell carcinoma (HNSCC), the sixth leading cancer worldwide. Most patients with HNSCC present with advanced disease ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. SPNS2 inhibitors as renal fibrosis therapy

    SBC: Flux Therapeutics, LLC            Topic: 400

    Fibrosis is an aberrant wound healing process characterized by progressive accumulation of extracellular matrix that ultimately destroys organ function. Progressive fibrosis is inherent to chronic kidney disease (CKD), which often leads to end-stage renal disease. Although patients can be maintained by hemodialysis while awaiting transplantation, their’s and their care-giver’s quality of life ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. An adjustable stiffness orthosis to maintain muscle engagement and push-off power in cerebral palsy.

    SBC: BIOMOTUM, INC.            Topic: NICHD

    PROJECT SUMMARY/ABSTRACT Ankle foot orthoses (AFOs) are commonly prescribed to improve mobility for individuals with neurological disorders. AFOs are included in the standard of care for the majority of ambulatory children with cerebral palsy (CP), a pediatric-onset movement disorder caused by insult to the developing brain. Current goals of treatment for individuals with CP center around increasi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government